The Drosophila RASSF Homolog Antagonizes the Hippo Pathway
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Correct organ size is determined by the balance between cell death and proliferation. Perturbation of this delicate balance leads to cancer formation . Hippo (Hpo), the Drosophila ortholog of MST1 and MST2 (Mammalian Sterile 20-like 1 and 2) is a key regulator of a signaling pathway that controls both cell death and proliferation . This pathway is so far composed of two Band 4.1 proteins, Expanded (Ex) and Merlin (Mer), two serine/threonine kinases, Hpo and Warts (Wts), the scaffold proteins Salvador (Sav) and Mats, and the transcriptional coactivator Yorkie (Yki). It has been proposed that Ex and Mer act upstream of Hpo, which in turn phosphorylates and activates Wts. Wts phosphorylates Yki and thus inhibits its activity and reduces expression of Yki target genes such as the caspase inhibitor DIAP1 and the micro RNA bantam. However, the mechanisms leading to Hpo activation are still poorly understood. In mammalian cells, members of the Ras association family (RASSF) of tumor suppressors have been shown to bind to MST1 and modulate its activity . In this study, we show that the Drosophila RASSF ortholog (dRASSF) restricts Hpo activity by competing with Sav for binding to Hpo. In addition, we observe that dRASSF also possesses a tumor-suppressor function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway
Udan, R. S., Kango-Singh, M., Nolo, R., Tao, C., & Halder, G. (2003) · Nature Cell Biology · doi:10.1038/ncb1050 · Cited by 747 · cited 1×
“First, we made clones that are mutant for two hpo hypomorphic alleles, hpo ([19] compare Figures 4C and 4F), hpo ([23] not shown), that remove the SARAH domain in a dRASSF mutant background in the head by using the eyeless FLP system [24].”
Cited by
The Hippo Signaling Pathway in Development and Cancer
Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.09.011 · Cited by 2,269
The Hippo pathway: regulators and regulations.
Yu, F.-X., & Guan, K.-L. (2013) · Genes & Development · doi:10.1101/gad.210773.112 · Cited by 1,231
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal
Zhao, B., Tumaneng, K., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2303 · Cited by 1,205
“In Drosophila , however, dRASSF inhibits Hpo possibly through competition with Sav for Hpo bindin”
Hippo signaling: growth control and beyond
Halder, G., & Johnson, R. L. (2011) · Development · doi:10.1242/dev.045500 · Cited by 1,060
Transduction of mechanical and cytoskeletal cues by YAP and TAZ
Halder, G., Dupont, S., & Piccolo, S. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3416 · Cited by 985
The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
Johnson, R., & Halder, G. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4161 · Cited by 881
Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP
Hao, Y., Chun, A., Cheung, K., Rashidi, B., & Yang, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709037200 · Cited by 786
The Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Harvey, K., & Tapon, N. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2070 · Cited by 628
Self-citationYAP and TAZ: a nexus for Hippo signaling and beyond
Hansen, C. G., Moroishi, T., & Guan, K.-L. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.05.002 · Cited by 574
Epithelial cell polarity, stem cells and cancer
Martin-Belmonte, F., & Perez-Moreno, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3169 · Cited by 552
The Hippo–YAP pathway: new connections between regulation of organ size and cancer
Zhao, B., Lei, Q.-Y., & Guan, K.-L. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.10.001 · Cited by 455
Couzens, A. L., Knight, J. D. R., Kean, M. J., Teo, G., Weiss, A., Dunham, W. H., Lin, Z.-Y., Bagshaw, R. D., Sicheri, F., Pawson, T., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004712 · Cited by 441
Donninger, H., Vos, M. D., & Clark, G. J. (2007) · Journal of Cell Science · doi:10.1242/jcs.010389 · Cited by 440
Matallanas, D., Romano, D., Yee, K., Meissl, K., Kucerova, L., Piazzolla, D., Baccarini, M., Vass, J. K., Kolch, W., & O'Neill, E. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.008 · Cited by 416
Kibra Is a Regulator of the Salvador/Warts/Hippo Signaling Network
Genevet, A., Wehr, M. C., Brain, R., Thompson, B. J., & Tapon, N. (2010) · Developmental Cell · doi:10.1016/j.devcel.2009.12.011 · Cited by 402
Self-citationSaucedo, L. J., & Edgar, B. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2221 · Cited by 363
Lgl, aPKC, and Crumbs Regulate the Salvador/Warts/Hippo Pathway through Two Distinct Mechanisms
Grzeschik, N. A., Parsons, L. M., Allott, M. L., Harvey, K. F., & Richardson, H. E. (2010) · Current Biology · doi:10.1016/j.cub.2010.01.055 · Cited by 346
The RASSF proteins in cancer; from epigenetic silencing to functional characterization
Richter, A. M., Pfeifer, G. P., & Dammann, R. H. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.004 · Cited by 295
The Ras-association domain family (RASSF) members and their role in human tumourigenesis
van der Weyden, L., & Adams, D. J. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.06.003 · Cited by 284
Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins
Reddy, B. V. V. G., & Irvine, K. D. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.01.020 · Cited by 271
Ajuba Family Proteins Link JNK to Hippo Signaling
Sun, G., & Irvine, K. D. (2013) · Science Signaling · doi:10.1126/scisignal.2004324 · Cited by 153
Alveolar rhabdomyosarcoma–associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression
Crose, L. E. S., Galindo, K. A., Kephart, J. G., Chen, C., Fitamant, J., Bardeesy, N., Bentley, R. C., Galindo, R. L., Ashley Chi, J.-T., & Linardic, C. M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67087 · Cited by 124
“RASSF4 is most similar to RASSFs 2 and 6 (26, 53), which have also been proven to inhibit Hippo signaling (54).”
Zheng, Y., Liu, B., Wang, L., Lei, H., Pulgar Prieto, K. D., & Pan, D. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.076 · Cited by 110
“Irrespective of the validity of this model, the fact that loss of Rassf leads to a much milder phenotype in Drosophila (Polesello et al., 2006) than loss of Slmap or mutating the Slmap docking sites in Hpo suggests the Slmap-mediated mechanism is likely more critical in the context of organ development, a proposition…”
BackgroundInfluentialSTRIPAK complexes in cell signaling and cancer
Shi, Z., Jiao, S., & Zhou, Z. (2016) · Oncogene · doi:10.1038/onc.2016.9 · Cited by 103
Mob Family Proteins: Regulatory Partners in Hippo and Hippo-Like Intracellular Signaling Pathways
Duhart, J. C., & Raftery, L. A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00161 · Cited by 33
Metadata
- Authors
- Polesello, C., Huelsmann, S., Brown, N. H., & Tapon, N.
- Venue
- Current Biology
- Publisher
- Elsevier BV
- Published
- 2006-12
- Volume
- 16
- Issue
- 24
- Pages
- 2459-2465
- ISSN
- 0960-9822 (ISSN-L)
- OpenAlex
- W1976356130
- Cited by
- 151
- References
- 1
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.